Open an account

Assertio Holdings

ASRT · NASDAQ

Price unavailable right now.

No price history for this range.

About ASRT

Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The company is headquartered in Lake Forest, Illinois and currently employs 53 full-time employees. The firm has built its commercial portfolio through the acquisition or licensing of approved products. Its commercial capabilities include marketing through both a sales force and an omni-channel promotion model, market access through payor contracting, and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, and CAMBIA (diclofenac potassium for oral solution). INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID). Otrexup is a once weekly single-dose auto-injector containing methotrexate.

Employees
53
Headquarters
Lake Forest, Illinois
Listed
Feb 12, 1997
Sector
Health Care
Industry
Pharmaceuticals
Website
assertiotx.com

ASRT key statistics

This section is temporarily unavailable. Refresh to try again.

Analyst ratings

Latest rating from each analyst over the past 12 months

0%of 2 analyst ratings say Buy
  • Buy0.0%
  • Hold100.0%
  • Sell0.0%
Price target · 5 analystsAvg $24.92
Low
$22.02
High
$29.40

ASRT earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 85.5% on average.

  1. Q2 FY24: reported -$0.60 per share against an estimate of -$0.4896
  2. Q3 FY24: reported -$0.45 per share against an estimate of -$0.7038
  3. Q4 FY24: reported -$1.65 per share against an estimate of -$0.6732
  4. Q1 FY25: reported -$0.60 per share against an estimate of -$0.918
  5. Q2 FY25: reported -$2.55 per share against an estimate of -$1.16
  6. Q3 FY25: reported $1.80 per share against an estimate of -$1.30
  7. Q4 FY25: reported -$1.86 per share against an estimate of -$2.76
  8. Q1 FY26: reported -$2.93 per share against an estimate of -$1.87

ASRT news

  • Press releaseBusiness Wire

    Assertio Announces Completion of Merger with Zydus Lifesciences and Fundamental Change and Make-Whole Fundamental Change Relating to its Outstanding 6.50% Convertible Senior Notes due 2027

  • Press releasePRNewswire

    Are SUNE, RLYB, ASRT, TMHC Obtaining Fair Deals for their Shareholders?

  • Press releasePRNewswire

    Are SILA, UNF, ASRT, KW Obtaining Fair Deals for their Shareholders?

  • Press releasePRNewswire

    $HAREHOLDER ALERT: The M&A Class Action Continues to Investigate the Merger--ASRT, SILA, KW, and UNF

  • Press releasePRNewswire

    Are SEM, UNF, CNTA, ASRT Obtaining Fair Deals for their Shareholders?

  • Press releaseBusiness Wire

    Assertio Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Assertio Holdings, Inc. - ASRT

  • Press releasePRNewswire

    Shareholder Alert: Ademi LLP investigates whether Assertio Holdings Inc. is obtaining a Fair Price for Public Shareholders

  • Press releaseBusiness Wire

    Assertio to Be Acquired by Zydus Worldwide DMCC for $23.50 Per Share in Cash

Similar companies

Companies in the same industry as Assertio Holdings

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.